Endometriosis Isn't Just a Reproductive Problem and the Numbers Prove It

Start Here

Most women with endometriosis are told they have a reproductive condition. The uterine-like tissue grows where it shouldn't. The pain is real. The lesions are real. The fertility impact is real. And the clinical conversation stays almost entirely in the pelvis.

That framing misses most of what's actually happening. Endometriosis is not primarily a pelvic problem. It's a systemic cellular energy failure that expresses itself most visibly in pelvic tissue. The distinction matters enormously, because it determines what a realistic approach to the condition looks like and why the interventions most commonly offered, hormonal suppression and surgery, address the expression of the problem while leaving the mechanism that produces it completely intact.

The Statistics That Change How This Condition Has to Be Understood

Endometriosis is not officially classified as an autoimmune disease. But the research from the Nuffield Department of Women's and Reproductive Health at the University of Oxford makes a compelling case that the distinction may be more administrative than biological.

Individuals with endometriosis have a 14 percent higher risk of developing at least one autoimmune disease compared to those without it. A 21 percent higher risk of developing two. And a 30 percent higher risk of developing three or more autoimmune conditions. Research consistently documents a 30 to 80 percent elevated risk of developing a range of autoimmune and inflammatory conditions overall.

The conditions that follow an endometriosis diagnosis with the greatest frequency are not random. Research identifies elevated risk for rheumatoid arthritis, where studies point to a potential causal link at the cellular level. Hashimoto's thyroiditis shows high prevalence, particularly among women with endometriosis-related infertility. Multiple sclerosis shares strong genetic correlations with endometriosis. Systemic lupus erythematosus, psoriasis, and celiac disease all show significantly elevated rates in this population. And a major finding from the Oxford research is that these secondary diagnoses tend to cluster within approximately two years of the initial endometriosis diagnosis, not decades later.

A 30 percent higher risk of developing three or more autoimmune diseases. A clustering of secondary diagnoses within two years. These are not incidental findings. They describe a systemic process that the reproductive framing doesn't account for.

The shared biological pathways between endometriosis and autoimmune disease include genetic variants that regulate inflammation, immune dysregulation that allows displaced tissue to survive outside the uterus rather than being destroyed, and abnormal B-cell activation producing autoantibodies that are the hallmark of traditional autoimmune conditions. These are not separate phenomena occurring alongside endometriosis. They are features of the same underlying process.

What Mitochondrial Dysfunction Is Actually Doing in Endometrial Tissue

The connection between endometriosis and autoimmune disease runs through the same mechanism documented across the other conditions in this series: mitochondrial DNA damage generating an immune response the body cannot resolve because the source of the damage keeps running.

In healthy endometrial tissue, cells rely on a process called mitochondrial oxidative phosphorylation to produce energy efficiently. This is where the mitochondria use oxygen, to generate the maximum amount of ATP as a fuel source for energy, and the tissue functions and regenerates normally. In endometriosis, that process breaks down. Research published in ScienceDirect and PubMed Central documents a metabolic shift called Warburg-like reprogramming, in which severely damaged mitochondria shut down oxygen-dependent energy production and shift to anaerobic glycolysis, which severely limits the energy output. This Warburg Shift is the same metabolic state seen in rapidly proliferating cancer cells.

The consequences of this shift are specific and cumulative. Tissue running on glycolysis instead of oxidative phosphorylation produces only a fraction of the ATP that healthy mitochondrial function generates. It becomes starved of oxygen, of cellular energy, and of the hydration that normal cellular processes require. Tissue in that state doesn't regenerate cleanly. It proliferates, thickens, and stiffens, because the mitochondrial function that would govern normal regeneration and normal cellular turnover is no longer running correctly.

Simultaneously, malfunctioning mitochondria begin leaking reactive oxygen species (ROS) as inflammation into the surrounding tissue. Those excess ROS destroy cellular components, activate systemic inflammatory pathways, and drive the chronic pelvic pain and body-wide fatigue that most endometriosis patients experience as their most debilitating symptoms.

Endometrial tissue in Warburg shift is oxygen-deprived, energy-deprived, and running on a fraction of normal ATP output. Tissue in that state proliferates and stiffens rather than regenerating. The same mitochondrial damage drives both the lesions and the systemic inflammation.

How the Mitochondrial Damage Becomes an Immune Reaction

When mitochondria sustain enough damage, their membranes rupture and fragments of mitochondrial DNA leak into the cell's cytoplasm and the surrounding pelvic fluid. As covered elsewhere in this series, mitochondrial DNA is structurally similar to bacterial DNA. The immune system's pattern recognition receptors, specifically the cGAS-STING pathway and the NLRP3 inflammasome, cannot distinguish leaked mitochondrial DNA from a bacterial invader.

In endometriosis, the NLRP3 inflammasome becomes chronically overactivated. Pelvic macrophages and mast cells continuously release aggressive cytokines, particularly interleukin-1 beta and interleukin-18. This sustained immune activation exhausts the macrophages that would otherwise clear the displaced tissue. Instead of eliminating the lesions, the exhausted immune cells permit them to grow while remaining in a persistently activated state.

Over time, the massive volume of cellular debris and altered proteins produced by oxidative stress gets continuously presented to B-cells. The immune system gradually loses its ability to distinguish self from non-self. Autoantibodies develop that can target healthy organs at distant sites, the thyroid in Hashimoto's, the joint tissue in rheumatoid arthritis. The endometriosis is not causing those conditions as separate events. It's the same mitochondrial process reaching new tissues as the immune exhaustion deepens and the damage to mitochondrial DNA (called heteroplasmy) spreads.

The immune system in endometriosis is responding accurately to leaked mitochondrial DNA it reads as bacterial invasion. It isn't making a mistake. It can't resolve the problem because the source of the leak keeps running.

Why the Tissue Scars and Why Removing the Scar Doesn't Solve It

Any tissue that stays inflamed long enough will produce scar tissue. This is not a pathology specific to endometriosis. It's a universal biological response to sustained inflammation, and endometrial tissue running in chronic Warburg shift with continuous mitochondrial leaking and immune activation is generating the exact conditions that produce it.

The deeper mechanism involves direct current. Healthy tissue maintains a specific electrical environment that governs whether cells regenerate normally or shift into abnormal proliferation. Direct current, produced by the body through light absorption, nerve signaling, and mitochondrial function, is what keeps that electrical environment stable. When mitochondrial function fails and direct current drops, the tissue loses the electrical signal that tells it to regenerate. Without that signal, inflammation drives the tissue toward thickening and scarring rather than normal cellular turnover.

Surgery removes the visible scar tissue. It does not restore the mitochondrial function that produced it. A Warburg-shifted tissue environment with ongoing mitochondrial damage and continuous immune activation is the same environment after surgery as it was before. The scar tissue returns because the conditions generating it haven't changed. Research confirms this pattern: endometriosis recurrence after surgical excision is well-documented, and the recurrence rate reflects a process that the surgery addressed at the surface while the underlying mechanism continued undisturbed.

There is also a specific compounding problem with surgical intervention. Surgical tissue trauma is itself an inflammatory event in tissue that is already running in a chronic inflammatory state. In a body with adequate mitochondrial function and normal healing capacity, surgical trauma heals cleanly. In Warburg-shifted tissue with suppressed mitophagy and exhausted immune regulation, the surgical trauma can accelerate the very scarring process it was intended to address. Not to mention healing from a surgical scar requires the body to make more scar tissue.

Scar tissue in endometriosis is the result of sustained inflammation in tissue that has lost its normal direct current environment. Surgery removes the scar without restoring the mitochondrial conditions that prevented it from forming. The same process produces the same result.

Why Estrogen Gets Blamed and What's Actually Behind It

Estrogen dominance is the most commonly cited hormonal explanation for endometriosis, and the relationship is real. Endometrial tissue is estrogen-dependent. Excess estrogen metabolites drive its growth. The standard clinical response, hormonal suppression, follows logically from that observation.

What doesn't typically get explained is why estrogen dominance develops in the first place, and what it's connected to upstream.

Estrogen is processed through a two-phase detoxification pathway. Phase one converts it, and phase two removes it. Phase two depends on methylation, the biochemical process that tags compounds for elimination and governs a range of regulatory functions including DNA repair, neurotransmitter production, and immune signaling. When methylation is impaired, toxic estrogen metabolites aren't cleared efficiently. They accumulate in the system, driving estrogen dominance even when total estrogen levels on a blood test appear normal. Most standard testing doesn't measure the metabolites. It measures total levels and misses the problem entirely.

Methylation impairment doesn't appear randomly. It connects directly to the same energy system failure driving the rest of the picture. When cells shift into Warburg metabolism, methylation capacity decreases as the body redirects resources toward immediate energy production and away from regulatory maintenance. The body will protect methyl groups for stress response signaling before it uses them for estrogen clearance. Poor methylation also tracks directly with inadequate morning light exposure, which is relevant because the B vitamin cofactors required for methylation pathways absorb light at frequencies found in morning sunlight.

Suppressing estrogen pharmacologically reduces the fuel supply to estrogen-dependent tissue. It doesn't restore methylation. It doesn't address the Warburg shift producing the methylation failure. When the hormonal suppression is stopped, the same impaired clearance pathway is still there, and the same metabolite accumulation begins again.

Estrogen dominance in endometriosis is frequently a methylation clearance problem downstream of mitochondrial energy failure. Suppressing estrogen addresses the fuel supply without restoring the system that should be clearing it.

The Hormone Nobody Talks About in Endometriosis

Leptin is the hormone that sits between what the mitochondria are doing and what the hypothalamus decides to do about it. It governs energy metabolism, hormone signaling, immune regulation, and the feedback loops that connect the pituitary, the thyroid, and every downstream hormone system in the body.

In women with endometriosis, leptin levels are significantly elevated. Research identifies this as a driver of lesion survival and growth, because elevated peritoneal leptin creates a pro-proliferative environment for ectopic tissue. But the clinical conversation rarely goes further than that observation.

The more important piece is what leptin resistance does to the entire hormone governing system. Leptin communicates upward to the hypothalamus and pituitary, which then regulate every hormone cascade below them. When the hypothalamus stops reading leptin signals correctly, the entire downstream hormone architecture becomes unreliable. Thyroid function, cortisol regulation, reproductive hormones, MSH production, and the immune modulation that MSH governs all depend on signals that originate at the top of that system. When leptin resistance disrupts the top, every level below it drifts.

MSH, melanocyte-stimulating hormone, is directly suppressed when leptin signaling fails. Low MSH is associated with chronic pain amplification, immune dysregulation, poor sleep, low DHEA, and elevated interleukin-6. These are not separate symptoms the endometriosis patient happens to have. They're the predictable downstream result of a leptin and MSH disruption running in parallel with the mitochondrial damage and Warburg shift.

Hormonal replacement and suppression work at the bottom of this cascade. The signal disruption at the hypothalamic and pituitary level that produces the hormonal abnormality remains untouched.

Leptin governs the entire hormone cascade from hypothalamus to pituitary to every downstream system. Leptin resistance in endometriosis disrupts that governing signal, which means every hormone managed by that system is operating on unreliable instructions regardless of what's done at the individual hormone level.

Why the Autoimmune Risk Compounds Over Time

The autoimmune statistics from the Oxford research make more sense once the mechanism is clear. The endometriosis patient isn't developing rheumatoid arthritis, Hashimoto's, and lupus as three separate misfortunes. They're experiencing the same mitochondrial energy failure reaching new tissues as the process continues unaddressed.

Heteroplasmy, the proportion of damaged mitochondrial DNA in a cell, accumulates over time when the process driving it runs without being addressed. As heteroplasmy increases across multiple tissues, more tissues cross the threshold at which normal function fails and the immune system's distress response activates in that location. The first diagnosis reflects the first tissue to cross that threshold. The second and third diagnoses reflect what was already in process.

This also explains why the secondary diagnoses cluster within two years of the endometriosis diagnosis rather than appearing decades later. By the time endometriosis becomes clinically visible, the underlying process has typically been running for years. The subsequent diagnoses aren't new developments. They're the same process that was already underway becoming detectable in additional locations.

Research confirms that 50 percent of people with one autoimmune diagnosis already have a second autoimmune process developing by the time they receive the first. For endometriosis patients, the evidence suggests this timeline may be even more compressed, given the systemic mitochondrial involvement and immune exhaustion that the condition produces.

By the time endometriosis is diagnosed, the process driving it has usually been running for years. The autoimmune conditions that follow within two years were already in development.

What the Data Is Actually Saying

The research reviewed here draws a consistent picture. Endometriosis shares its root mechanism with autoimmune disease because it originates in the same place: mitochondrial energy failure driving a Warburg metabolic shift, generating a chronic immune response to leaked mitochondrial DNA, producing scar tissue in low direct current environments, disrupting leptin and MSH signaling at the governing level, impairing methylation and estrogen clearance downstream, and accumulating heteroplasmy that spreads the process to additional tissues.

The current treatment model addresses several points downstream of that origin. Hormonal suppression reduces the fuel supply to estrogen-dependent tissue. Surgery removes the visible result of the inflammatory process. Pain management addresses the symptom produced by the cytokine cascade. Each of those interventions only has value as symptom management. None of them reaches the level where the process starts.

The researchers at the University of Oxford, in the same paper documenting the autoimmune risk statistics, describe the clinical implication directly: recognizing this link transforms how endometriosis has to be treated. Rather than as a pelvic or reproductive issue, it requires comprehensive whole-body evaluation. That framing is accurate. What it requires at the mechanism level is evaluation and intervention at the mitochondrial energy system that is generating the entire cascade.

If the underlying process isn't addressed, the trajectory the statistics document isn't a risk. It's a schedule.

Find Out What the Mitochondrial Pattern Looks Like in Your Case

Endometriosis. The autoimmune conditions that follow. The hormone dysregulation beneath it.

These aren't separate problems. An evaluation shows the full picture.

[ SCHEDULE YOUR CONSULTATION ]

Dr. Rob DeMartino D.C. | Energetic Debt Method

This article is educational and does not constitute individual medical advice. Outcomes vary by patient and condition.

Conventional medical care vs. Superior Health Solutions natural healthcare

Related video